Keyword: Gilead Sciences

Gilead's Truvada for PrEP is only getting to about 10% of people who could benefit, according to testimony Thursday.

Gilead has reaped billions of dollars in sales from "unlawfully monopolized" HIV drugs, patients and activists say in a new class action lawsuit.

Gilead must face claims that it delayed developing its safer, next-generation HIV meds to reap as much revenue as possible from its older drugs. 

With HIV rates in the U.S. holding steady, health officials are looking to drugmakers to help drive down infections. Now, Gilead is ready to chip in.

Gilead has previously indicated big-selling HIV drug Truvada wouldn't face generic competition until 2021. Now, Teva can launch next year, the company says.

Gilead Sciences, with its HIV launch Biktarvy, joins AbbVie and Pfizer as the top three pharma TV ad spenders in April, according to iSpot.tv data.

Gilead tapped new CEO Daniel O’Day in part because of his cancer expertise. But he’s not planning to lead the company’s oncology ramp-up alone.

Gilead CFO Robin Washington plans to retire next March, giving brand-new CEO Daniel O'Day his first C-suite slot to fill.

As U.S. states partner with hepatitis C drug makers on Netflix-style contracts, England is teaming up with pharma in its own effort to eradicate the disease. 

With Yescarta on the market and other CAR-Ts on their way, Gilead’s Kite Pharma planted the flag for another manufacturing site.